+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drugs For Benign Prostatic hypertrophy Global Market Report 2020

  • ID: 4871559
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • AEternaZentaris Inc.
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • GemVax & KAEL Co. Ltd.
  • GlaxoSmithKline PLC
  • Ipsen S.A.
  • MORE
Drugs For Benign Prostatic hypertrophy Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global drugs for benign prostatic hypertrophy market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the drugs for benign prostatic hypertrophy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Drugs For Benign Prostatic hypertrophy Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others 2) By End User: Hospital Pharmacies, Retail Pharmacies, Others
  • Companies Mentioned: Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AEternaZentaris Inc.
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • GemVax & KAEL Co. Ltd.
  • GlaxoSmithKline PLC
  • Ipsen S.A.
  • MORE
1. Executive Summary

2. Drugs for Benign Prostatic Hypertrophy Market Characteristics

3. Drugs for Benign Prostatic Hypertrophy Market Size And Growth
3.1. Global Drugs for Benign Prostatic Hypertrophy Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Drugs for Benign Prostatic Hypertrophy Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Drugs for Benign Prostatic Hypertrophy Market Segmentation
4.1. Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Alpha Blocker
5-alpha Reductase Inhibitor
  • Phosphodiesterase-5 Inhibitor
  • Others
4.2. Global Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
5. Drugs for Benign Prostatic Hypertrophy Market Regional And Country Analysis
5.1. Global Drugs for Benign Prostatic Hypertrophy Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Drugs for Benign Prostatic Hypertrophy Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market
6.1. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market Overview
6.2. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Drugs for Benign Prostatic Hypertrophy Market
7.1. China Drugs for Benign Prostatic Hypertrophy Market Overview
7.2. China Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Drugs for Benign Prostatic Hypertrophy Market
8.1. India Drugs for Benign Prostatic Hypertrophy Market Overview
8.2. India Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Drugs for Benign Prostatic Hypertrophy Market
9.1. Japan Drugs for Benign Prostatic Hypertrophy Market Overview
9.2. Japan Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Drugs for Benign Prostatic Hypertrophy Market
10.1. Australia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Drugs for Benign Prostatic Hypertrophy Market
11.1. Indonesia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Drugs for Benign Prostatic Hypertrophy Market
12.1. South Korea Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Drugs for Benign Prostatic Hypertrophy Market
13.1. Western Europe Drugs for Benign Prostatic Hypertrophy Market Overview
13.2. Western Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Drugs for Benign Prostatic Hypertrophy Market
14.1. UK Drugs for Benign Prostatic Hypertrophy Market Overview
14.2. UK Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Drugs for Benign Prostatic Hypertrophy Market
15.1. Germany Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Drugs for Benign Prostatic Hypertrophy Market
16.4. France Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market
17.1. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market Overview
17.2. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Drugs for Benign Prostatic Hypertrophy Market
18.1. Russia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Drugs for Benign Prostatic Hypertrophy Market
19.1. North America Drugs for Benign Prostatic Hypertrophy Market Overview
19.2. North America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Drugs for Benign Prostatic Hypertrophy Market
20.1. USA Drugs for Benign Prostatic Hypertrophy Market Overview
20.2. USA Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Drugs for Benign Prostatic Hypertrophy Market
21.1. South America Drugs for Benign Prostatic Hypertrophy Market Overview
21.2. South America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Drugs for Benign Prostatic Hypertrophy Market
22.1. Brazil Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Drugs for Benign Prostatic Hypertrophy Market
23.1. Middle East Drugs for Benign Prostatic Hypertrophy Market Overview
23.2. Middle East Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Drugs for Benign Prostatic Hypertrophy Market
24.1. Africa Drugs for Benign Prostatic Hypertrophy Market Overview
24.2. Africa Drugs for Benign Prostatic Hypertrophy Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Drugs for Benign Prostatic Hypertrophy Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Drugs for Benign Prostatic Hypertrophy Market Competitive Landscape And Company Profiles
25.1. Drugs for Benign Prostatic Hypertrophy Market Competitive Landscape
25.2. Drugs for Benign Prostatic Hypertrophy Market Company Profiles
25.2.1. Allergan PLC
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Astellas Pharma Inc.
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Boehringer Ingelheim
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Eli Lilly and Company
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. GlaxoSmithKline PLC
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Drugs for Benign Prostatic Hypertrophy Market

27. Drugs for Benign Prostatic Hypertrophy Market Trends And Strategies

28. Product Pipeline Analysis

29. Drugs for Benign Prostatic Hypertrophy Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AEternaZentaris Inc.
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • GemVax & KAEL Co. Ltd.
  • GlaxoSmithKline PLC
  • Ipsen S.A.
  • MORE
The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50.

The global drugs for benign prostatic hypertrophy market was valued at about $4.03 billion in 2018 and is expected to grow to $5.65 billion at a CAGR of 8.8% through 2022.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2018, followed by Europe and Asia Pacific. This region is expected to remain the largest during the next five years. The drugs for benign prostatic hypertrophy market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The rising male geriatric population globally is driving the market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2017 World Population Ageing Report, the number of people aged 60 years or above was 962 million in 2017 and is expected to double to around 2.1 billion by 2050. According to the National Institute of Health( NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA).

Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.

Benign prostatic hypertrophy drugs manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate safety and efficacy of drugs using clinical trials data which will be assessed by competent authorities before authorizing for sale.

Major players in the market are Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC
Note: Product cover images may vary from those shown
5 of 5
  • Allergan PLC
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Limited
  • Sanofi
  • Nymox Pharmaceutical Corporation
  • AEternaZentaris Inc.
  • Pfizer Inc.
  • GlaxoSmithKline
  • IntelGenx Technologies Corp.
  • Ipsen S.A.
  • Novartis AG
  • Protox Therapeutics Inc.
  • Valeant Pharmaceuticals Inc.
  • Bayer AG
  • Quest PharmaTech Inc.
  • Bristol-Myers Squibb and Company
  • Indevus Pharmaceuticals Inc.
  • Kaken Pharmaceutical Co. Ltd.
  • Impax Laboratories Inc.
  • GemVax & KAEL Co. Ltd.
  • Merck & Co. Inc.
  • Kissei Pharmaceuticals Co. Ltd.
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll